Evaluation of hypoxia-inducible factor 1α overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma

BJU International

Volumn 95, Issue 3, 2005, Pages 425-431

  Theodoropoulos, Vasilios E ^a,c   Lazaris, Andreas C ^b   Kastriotis, Ioannis ^b   Spiliadi, Chariclia ^a   Theodoropoulos, George E ^b   Tsoukala, Vasiliki ^b   Patsouris, Efstratios ^b   Sofras, Frank ^a  

^a AGIA OLGA HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE   (Greece)

Author keywords

Angiogenesis; Apoptosis; Hypoxia; Progression; Recurrence; Urothelial bladder carcinoma

Indexed keywords

CD31 ANTIGEN; DNA ANTIBODY; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; MUTANT PROTEIN; PROTEIN BCL 2; PROTEIN P53; SINGLE STRANDED DNA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UROGENITAL TRACT CANCER; UROTHELIAL BLADDER CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 14144250813     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05314.x     Document Type: Article

References (30)

1. Hassen W, Droller MJ. Current concepts in assessment and treatment of bladder cancer. Curr Opin Urol 2000; 10: 291-9
2. Zhong H, De Marzo AM, Laughner E et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5
3. Brizel DM, Scully SP, Harrelson JM et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-3
4. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15: 551-78
5. Talks KL, Turley H, Gatter KC et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-21
6. 2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-4
7. Carmeliet P, Dor Y, Herbert JM et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-90
8. Korkolopoulou P, Konstantinidou AE, Christodoulou P et al. Apoptosis in bladder carcinomas detected with monoclonal antibody to single-stranded DNA. relation to cell cycle regulators and survival. Urology 2000; 56: 516-20
9. Korkolopoulou P, Lazaris ACh, Konstantinidou AE et al. Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol 2002; 41: 274-83
10. Onita T, Ji PG, Xuan JW et al. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res 2002; 8: 471-80
11. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8
12. Reiher F, Ozer O, Pins M, Jovanovic BD, Eggener S, Campbell SC. p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol 2002; 167: 1469-74
13. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60: 4693-6
14. Wang JM, Kumar S, Pye D, Haboubi N, al-Nakib L. Breast carcinoma. Comparative study of tumor vasculature using two endothelial cell markers. J Natl Cancer Inst 1994; 86: 386-8
15. Kausch I, Bohle A. Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer. Eur Urol 2002; 41: 15-29
16. Aebersold DM, Burri P, Beer KT et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911-6
17. Korkolopoulou P, Patsouris E, Konstantinidou AE et al. Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 2004; 30: 267-78
18. Jones A, Fujiyama C, Blanche C et al. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin Cancer Res 2001; 7: 1263-72
19. Mellon K, Neal DE, Robinson MC, Marsh C, Wright C. Cell cycling in bladder carcinoma determined by monoclonal antibody Ki67. Br J Urol 1990; 66: 281-5
20. Gontero P, Casetta G, Zitella A et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000; 38: 287-96
21. Stavropoulos NE, Ioackim-Velogianni E, Hastazeris K, Kitsiou E, Stefanaki S, Agnantis N. Growth fractions in bladder cancer defined by Ki67. Association with cancer grade, category and recurrence rate of superficial lesions. Br J Urol 1993; 72: 736-9
22. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA. The prevalence of bcl-2, 53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998; 29: 146-54
23. Lipponen PK, Aaltomaa S, Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumours. Histopathology 1996; 28: 135-40
24. Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, 53, and Ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000; 163: 758-60
25. Sagol O, Yorukoglu K, Sis B et al. Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder? Urology 2001; 57: 895-9
26. Dinney CP, Babkowski RC, Antelo M et al. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urol 1998; 160: 1285-90
27. Ozer E, Mungan MU, Tuna B, Kazimoglu H, Yorukoglu K, Kirkali Z. Prognostic significance of angiogenesis and immunoreactivity of cathepsin D and type IV collagen in high-grade stage T1 primary bladder cancer. Urology 1999; 54: 50-5
28. Goddard JC, Sutton CD, Furness PN, O'Byrne KJ, Kockelbergh RC. Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 2003; 9: 2583-6
29. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994; 74: 762-6
30. Hawke CK, Delahunt B, Davidson PJ. Microvessel density as a prognostic marker for transitional cell carcinoma of the bladder. Br J Urol 1998; 81: 585-90